NEWS

FOR IMMEDIATE RELEASE November 25, 2025  A new topical treatment may reduce post-mastectomy pain and opioid use by activating the endocannabinoid system (ECS) Vancouver, BC, Canada — A new hope for breast cancer patients, Andira Pharmaceuticals today announced FDA filing plans for a new topical treatment, AND-254, aimed at reducing pain after mastectomy

FOR IMMEDIATE RELEASE Andira’s Silvanex™ Shows Zero MRSA Resistance Potential in Landmark AMR Study Vancouver, BC – July 22, 2025 — Andira Pharmaceuticals, a global leader in cannabinoid-based therapeutics, today announced breakthrough results from an independent antimicrobial resistance (AMR) study conducted by Element Materials Technology. The study found that Silvanex™

FOR IMMEDIATE RELEASE Vancouver, BC — June 16, 2025 — Andira Pharmaceuticals Inc., a therapeutics company developing synergistic, cannabinoid-based treatments for oncology and infectious disease, today announced the successful completion of pre-clinical efficacy studies for AND-259, a first-in-class transdermal cannabinoid treatment for ductal carcinoma in situ (DCIS)—a highly prevalent, early-stage form of breast cancer